-
-
-
-
-
-
-
BioCryst Pharma (BCRX) PT Raised to $28 at Citizens Amid Steady New Patient Starts
-
-
-
-
-
-
-
TD Cowen Reiterates Buy Rating on BioCryst Pharma (BCRX)
-
-
-
-
-
-
-
BioCryst Pharma (BCRX) PT Raised to $32 at H.C. Wainwright
-
-
-
-
-
-
-
Cantor Fitzgerald Reiterates Overweight Rating on BioCryst Pharma (BCRX)
-
-
-
-
-
-
-
BioCryst Pharma (BCRX) PT Raised to $15 at RBC Capital Amid 10pct Decline
-
-
-
-
-
-
-
RBC Capital on BioCryst Pharma (BCRX): 'We See Shares Undervalued'
-
-
-
-
-
-
-
BioCryst Pharma (BCRX) Presents New Real-world Evidence Showing Significant and Sustained Reductions in HAE Attack Rates in Adolescents and People with Severe HAE Following Initiation of ORLADEYO
-
433,547 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

